(Q40754073)

English

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

scientific article published on 6 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

Jean-Charles Soria

1

object named as

Jean-Charles Soria

0 references

author name string

Yi-Long Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Kazuhiko Nakagawa

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sang-We Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Jin-Ji Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Myung-Ju Ahn

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Jie Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

James Chih-Hsin Yang

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

You Lu

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Shinji Atagi

10

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Santiago Ponce

11

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Dae Ho Lee

12

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Yunpeng Liu

13

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Kiyotaka Yoh

14

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Jian-Ying Zhou

15

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Xiaojin Shi

16

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Alan Webster

17

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Haiyi Jiang

18

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Tony S K Mok

19

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

publication date

6 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

990-998

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The quest to overcome resistance to EGFR-targeted therapies in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900121-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00121-7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40754073&oldid=1906699998"